Concert Pharmaceuticals Inc. (CNCE)

11.40
NASDAQ : Health Technology
Prev Close 10.91
Day Low/High 11.26 / 12.05
52 Wk Low/High 9.21 / 19.86
Avg Volume 317.10K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 259.61M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Concert Pharmaceuticals Reports Positive Results From Phase 1 Studies Evaluating CTP-692 In Healthy Volunteers

Concert Pharmaceuticals Reports Positive Results From Phase 1 Studies Evaluating CTP-692 In Healthy Volunteers

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.

Concert Pharmaceuticals Completes Enrollment In Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals Completes Enrollment In Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Concert Pharmaceuticals Announces Initiation Of New Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals Announces Initiation Of New Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The UBS Global Healthcare Conference on May 21, 2019 at 10:00 a.

Concert Pharmaceuticals Reports First Quarter 2019 Financial Results

Concert Pharmaceuticals Reports First Quarter 2019 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2019.

Concert Pharmaceuticals Names Jesper Høiland To Its Board Of Directors

Concert Pharmaceuticals Names Jesper Høiland To Its Board Of Directors

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately.

Concert Pharmaceuticals To Report First Quarter 2019 Financial Results On May 2, 2019

Concert Pharmaceuticals To Report First Quarter 2019 Financial Results On May 2, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019, before the U.

Concert Pharmaceuticals To Present CTP-543 Phase 2 Interim Data In Alopecia Areata At 2019 World Congress For Hair Research Annual Meeting

Concert Pharmaceuticals To Present CTP-543 Phase 2 Interim Data In Alopecia Areata At 2019 World Congress For Hair Research Annual Meeting

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11 th Annual World Congress for Hair...

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.

Concert Pharmaceuticals Is Now Oversold (CNCE)

Concert Pharmaceuticals Is Now Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Announces Decision From Patent Trial And Appeal Board In IPR Proceeding

Concert Pharmaceuticals Announces Decision From Patent Trial And Appeal Board In IPR Proceeding

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.

First Week Of May 17th Options Trading For Concert Pharmaceuticals (CNCE)

First Week Of May 17th Options Trading For Concert Pharmaceuticals (CNCE)

Investors in Concert Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CNCE options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

CNCE: Insiders Vs. Shorts

CNCE: Insiders Vs. Shorts

The most recent short interest data was recently released for the 03/15/2019 settlement date, and Concert Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 4.66 "days to cover" versus the median component at 4.33. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

CNCE Makes Notable Cross Below Critical Moving Average

CNCE Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Concert Pharmaceuticals Inc crossed below their 200 day moving average of $15.17, changing hands as low as $14.21 per share. Concert Pharmaceuticals Inc shares are currently trading off about 7.4% on the day.

First Week Of CNCE July 19th Options Trading

First Week Of CNCE July 19th Options Trading

Investors in Concert Pharmaceuticals Inc saw new options begin trading this week, for the July 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 123 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Concert Pharmaceuticals To Present At Upcoming Oppenheimer Healthcare Conference

Concert Pharmaceuticals To Present At Upcoming Oppenheimer Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Oppenheimer 29 th Annual Healthcare Conference on March 19, 2019 at 1:00 p.

Concert Pharmaceuticals Announces Initiation Of Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals Announces Initiation Of Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALRM, ATRS, CCK, CGC, FHN, FLGT, FND, GIFI, GTS, IMKTA, IONS, IROQ, LAWS, LEG, MANH, MOFG, NMFC, NPTN, NWN, RUN, VAC, WAL, XRAY Downgrades: ACHC, CNCE, HCI, ORBC, VMW Initiations: ALTR, FNKO, SE Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For CNCE

Concert Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For CNCE

In trading on Friday, shares of Concert Pharmaceuticals Inc crossed above their 200 day moving average of $15.47, changing hands as high as $15.72 per share. Concert Pharmaceuticals Inc shares are currently trading up about 3.4% on the day.

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data In Alopecia Areata During Late-Breaker Session At American Academy Of Dermatology Annual Meeting

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data In Alopecia Areata During Late-Breaker Session At American Academy Of Dermatology Annual Meeting

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during...

Concert Pharmaceuticals Reports Year Ended 2018 Financial Results And Provides Update On Clinical Programs

Concert Pharmaceuticals Reports Year Ended 2018 Financial Results And Provides Update On Clinical Programs

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2018, as well as provided an update on its product pipeline and corporate activities.

Concert Pharmaceuticals To Report Full Year 2018 Results On February 28, 2019

Concert Pharmaceuticals To Report Full Year 2018 Results On February 28, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2018, on Thursday, February 28, 2019, before the U.

Concert Pharmaceuticals Selected For Late-Breaking Oral Presentation Of CTP-543 Phase 2 Data In Alopecia Areata At 2019 AAD Annual Meeting

Concert Pharmaceuticals Selected For Late-Breaking Oral Presentation Of CTP-543 Phase 2 Data In Alopecia Areata At 2019 AAD Annual Meeting

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of...

Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia

Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.

Concert Pharmaceuticals Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.

Noteworthy Friday Option Activity: CNCE, UIHC, RDFN

Noteworthy Friday Option Activity: CNCE, UIHC, RDFN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Concert Pharmaceuticals Inc , where a total of 2,013 contracts have traded so far, representing approximately 201,300 underlying shares. That amounts to about 146.5% of CNCE's average daily trading volume over the past month of 137,375 shares.

CNCE: Insiders Vs. Shorts

CNCE: Insiders Vs. Shorts

The most recent short interest data was recently released for the 12/14/2018 settlement date, and Concert Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 4.94 "days to cover" versus the median component at 4.32. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Concert Pharmaceuticals Initiates Phase 1 Clinical Program Of CTP-692 For The Treatment Of Schizophrenia

Concert Pharmaceuticals Initiates Phase 1 Clinical Program Of CTP-692 For The Treatment Of Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with significant unmet...

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports Positive CTP-543 Results From Interim Analysis Of Phase 2a Trial In Patients With Alopecia Areata

Concert Pharmaceuticals Reports Positive CTP-543 Results From Interim Analysis Of Phase 2a Trial In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune...

TheStreet Quant Rating: D (Sell)